The economic evaluation of any human papillomavirus (HPV) vaccination strategy requires the measurement of clinical benefits (quality-adjusted life-years [QALY]) gained to reflect both the increase in life expectancy and the economic benefits associated with an effective intervention.
Mennini, F., Panatto, D., Marcellusi, A., Cristoforoni, P., De Vincenzo, R. P., Di Capua, E., Ferrandina, M. G., Petrillo, M., Sasso, T., Ricci, C. A., Trivellizzi, N., Capone, A., Scambia, G., Gasparini, R., Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy, <<CLINICAL THERAPEUTICS>>, 2011; 33 (8): 1084-1084-1095.e4. [doi:10.1016/j.clinthera.2011.06.012] [http://hdl.handle.net/10807/3706]
Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy
De Vincenzo, Rosa Pasqualina;Ferrandina, Maria Gabriella;Petrillo, Marco;Scambia, Giovanni;
2011
Abstract
The economic evaluation of any human papillomavirus (HPV) vaccination strategy requires the measurement of clinical benefits (quality-adjusted life-years [QALY]) gained to reflect both the increase in life expectancy and the economic benefits associated with an effective intervention.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.